 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | PCV7 / Pfizer, Pneumosil (10-valent pneumococcal conjugate vaccine) / Serum Institute of India, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Journal, HEOR, Real-world evidence, Real-world: Pneumococcal serotypes missing prespecified efficacy threshold in immunogenicity trials: real-world evidence from national immunization programs. (Pubmed Central) - Sep 27, 2024
The 13-valent (PCV13) and 10-valent (PCV10) pneumococcal conjugate vaccines missed non-inferiority for certain 7-valent (PCV7) serotypes in immunogenicity trials...Despite missing non-inferiority for serotypes in immunogenicity trials, higher-valent PCVs effectively suppressed these serotypes across all ages. Non-inferiority criteria from immunogenicity trials may not fully predict real-world disease impact after PCV implementation.
- | PCV7 / Pfizer, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Journal: Nasopharyngeal carriage of Streptococcus pneumoniae among children aged 30 days to <60 months in Beijing and Shenzhen, China (2018-2021) during pneumococcal conjugate vaccine introduction and the coronavirus disease (COVID-19) pandemic. (Pubmed Central) - Sep 25, 2024
Vaccination with PCV7 or PCV13 was associated with lower PCV13-serotype colonization. In Beijing, S. pneumoniae carriage significantly declined during the COVID-19 pandemic.
- || PCV7 / Pfizer, Pneumosil (10-valent pneumococcal conjugate vaccine) / Serum Institute of India, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Review, Journal: Effect of pneumococcal conjugate vaccines on viral respiratory infections: a systematic literature review. (Pubmed Central) - Sep 24, 2024
Limited evidence for adults was generally consistent with pediatric data. Restricting public health evaluations to confirmed pneumococcal outcomes may underestimate the full impact of PCVs.
- Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer
The Health and Economic Impact of the PCV15 and PCV20 Priming Series during the First Year of Life in the US (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2746;
- | Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina. (Pubmed Central) - Jun 16, 2024
Over a 10-year horizon, vaccination with PCV20 was expected to be the dominant, cost-saving strategy versus PCV13 and PCV15 in children in Argentina. Policymakers should consider the PCV20 vaccination strategy to achieve the greatest clinical and economic benefit compared with lower-valent options.
- | Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis. (Pubmed Central) - May 11, 2024
PCV20 3+1 dominated both PCV13 2+1 and PCV15 2+1 over 10 years. Replacing lower-valent PCVs with PCV20 would result in greater clinical and economic benefits, given PCV20's broader serotype coverage.
- | Pneumosil (10-valent pneumococcal conjugate vaccine) / Serum Institute of India, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Journal: Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance. (Pubmed Central) - Apr 22, 2024
In contrast to PCV10, PCV13 vaccination consistently protected against 6C IPD and NPC in children, and provided some level of indirect protection to adults, supporting that serotype 6A but not 6B provides cross-protection to 6C. Vaccine policy makers and regulators should consider the effects of serotype 6A-containing PCVs against serotype 6C disease in their decisions.
- Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
PNEUMOCOCCAL SEROTYPES ASSOCIATED WITH INVASIVE PNEUMOCOCCAL DISEASE AND CARRIAGE IN UK CHILDREN (Poster Area; Board 366) - Feb 24, 2024 - Abstract #ISPPD2024ISPPD_730;
These data suggest that PCV20 has the potential to substantially impact the remaining IPD burden and carriage of PCV20 serotypes in UK children. Contemporary data are needed to enable an understanding of the current contribution of PCV20 serotypes to disease and carriage.
- Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
ESTIMATED CLINICAL AND ECONOMIC IMPACT OF REPLACING PCV13 WITH PCV20 IN PEDIATRIC NATIONAL IMMUNIZATION PROGRAM IN ALGERIA (Poster Area; Board 466) - Feb 24, 2024 - Abstract #ISPPD2024ISPPD_678;
The introduction of PCV20 in Algeria is expected to reduce additional burden of PD and save more medical costs. Avilability of the local epidemiological data would better inform the benefit of PCV20 in Algeria.
- PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
PNEUMOCOCCAL SEROTYPE DISTRIBUTION IN ADULTS HOSPITALIZED WITH ACUTE RESPIRATORY INFECTION 12 YEARS AFTER OF INTRODUCTION OF PNEUMOCOCCAL CONJUGATE VACCINE IN JAPAN (Poster Area; Board 168) - Feb 24, 2024 - Abstract #ISPPD2024ISPPD_649;
These results indicate that following 12 years of PCV7/PCV13 use in children and PPSV23 in adults, PCV13 serotypes are relatively rare while PPSV23 unique serotypes (11A, 10A, and 15B) are relatively common in adults with hospitalized respiratory infection. These data can help inform pneumococcal vaccine strategies for adults as well as serotype selection for future vaccines.
- PCV7 / Pfizer, Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer
LONGITUDINAL ANALYSIS OF PNEUMOCOCCAL SEROTYPES IN PNEUMONIA PATIENTS IN GERMANY 2017-2021 (Poster Area; Board 428) - Feb 24, 2024 - Abstract #ISPPD2024ISPPD_458;
Despite being included in PCV13, ST03 has been evolved to be one of the leading ST. During the pandemic (2020+2021), other STs (ST6A and ST15B, both covered by PCV20) became more common.
- PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
IMMUNOGENICITY PROFILE IN HEALTHY INFANTS ACROSS STUDIES IN THE GLOBAL 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE PEDIATRIC CLINICAL PROGRAM (Poster Area; Board 321) - Feb 24, 2024 - Abstract #ISPPD2024ISPPD_422;
PCV13 licensure and subsequent introduction into national immunization programs was supported by demonstration of serotype-specific immune responses associated with functional activity, with priming for a vigorous booster response, for both the 2+1 and 3+1 schedules. Geographic and schedule-based variations in immunogenicity exist, emphasizing the need for direct comparison to a vaccine of known effectiveness in each study.
- PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
COST-EFFECTIVENESS ANALYSIS OF PNEUMOCOCCAL CONJUGATE VACCINES IN THAILAND (Poster Area; Board 465) - Feb 24, 2024 - Abstract #ISPPD2024ISPPD_341;
Estimates of direct and indirect vaccine effectiveness (VE) for the MM were derived from PCV10/PCV13 clinical effectiveness and PCV7 clinical efficacy studies, whereas the VE for DIFM was based on a real-world impact trend... Implementing a PCV10 or PCV13 NIP could prevent more PD cases in Thailand and were cost-effective compared with no vaccine, though in general PCV13 appear to be more cost-effective than PCV10.
- PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
SYSTEMATIC LITERATURE REVIEW OF PEDIATRIC ACUTE OTITIS MEDIA SINCE PNEUMOCOCCAL CONJUGATE VACCINE INTRODUCTION: S. PNEUMONIAE PREVALENCE, SEROTYPE DISTRIBUTION, AND ANTIBIOTIC NONSUSCEPTIBILITY (Poster Area; Board 170) - Feb 24, 2024 - Abstract #ISPPD2024ISPPD_312;
We systematically reviewed global studies published from July 2008 to December 2020 to describe Sp prevalence, serotype distribution (including the PCV20-nonPCV13 fraction due to serotypes 8, 10A, 11A, 12F, 15B/C, 22F, 33F), and antibiotic nonsusceptibility by pediatric PCV program (PCV7, PCV10, or PCV13) among children ?18 years old with OM, including acute OM (AOM) classified as such by the study investigators... AOM Sp prevalence and PCV20-nonPCV13 serotype distribution were associated with PCV choice for national immunization programs
- | Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants. (Pubmed Central) - Feb 5, 2024
AOM Sp prevalence and PCV20-nonPCV13 serotype distribution were associated with PCV choice for national immunization programs Infant vaccination with PCV20 is estimated to further reduce pneumococcal disease and associated healthcare system and societal costs compared to both PCV13 and PCV15.
- PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
7000 CHILDREN, 53 SEROTYPES AND 17 YEARS: THE STORY OF PAEDIATRIC PNEUMOCOCCAL CARRIAGE SURVEILLANCE ON ENGLAND'S SOUTH COAST (Meeting Room 1.60) - Jan 4, 2024 - Abstract #ISPPD2024ISPPD_58;
Methods The study started during the roll-out of PCV7 in 2006...Finally, since 2009/10 the greatest proportion of MDR isolates (21.1%) was serotype 15A (notably ST63), although MDR frequency has remained low overall. Conclusions Ongoing pneumococcal carriage surveillance highlights emerging trends in serotype epidemiology that can be used to guide vaccine design and implementation.
- PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
MOLECULAR STRATEGIES REVEAL PERSISTENCE OF 13 VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV) SEROTYPES IN HIGHLY IMMUNIZED CHILDREN (Meeting Room 1.60) - Jan 4, 2024 - Abstract #ISPPD2024ISPPD_56;
Background Studies of nasopharyngeal (NP) colonization in Massachusetts' children following the introduction of PCV7 reported declining prevalence of vaccine serotypes (VST), and increases in 6C, 7F, and 19A carriage...Conclusions Our results support the hypothesis that VSTs persist in immunized pediatric populations at densities below those detectable by culture. Our results are consistent with results from challenge studies reporting that molecular detection was more sensitive than culture methods in PCV13 immunized adults.
- PCV7 / Pfizer, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
HEALTHCARE WORKERS MAY SERVE AS AN UNRECOGNIZED RESERVOIR OF PNEUMOCOCCUS IN THE POPULATION (Meeting Room 1.60) - Jan 4, 2024 - Abstract #ISPPD2024ISPPD_55;
This study highlights that healthcare workers may act as unrecognized reservoirs of pneumococcus in the population. Despite long-standing PCV7 and PCV13 pediatric immunization programs, vaccine serotypes continue to be prevalent among an adult population.
- | PCV7 / Pfizer, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Journal: Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use. (Pubmed Central) - Jan 2, 2024
Despite long-standing PCV7 and PCV13 pediatric immunization programs, vaccine serotypes continue to be prevalent among an adult population. Robust ongoing surveillance networks are critical for identifying emerging serotypes and development of next-generation vaccine formulations.
- Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer
Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2055;
- Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer
Cost-Effectiveness Analysis of Catch-Up Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2054;
- SYSTEMATIC LITERATURE REVIEW OF THE EFFECTIVENESS AND IMPACT OF PCV13 FOR CHILDREN WITH OTITIS MEDIA (STATION 6) - Apr 21, 2023 - Abstract #ESPID2023ESPID_738;
VE against PCV13-type OM was 62% (non-significant), 77.4%, and 86.4%. Two studies also demonstrated 86% and 67.7% VE against the 6 PCV13-nonPCV7 serotypes.
- PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Systematic Literature Review of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) Effectiveness Against Invasive Pneumococcal Disease in Children Globally (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2085;
- PCV7 / Pfizer, Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer
STREPTOCOCCUS PNEUMONIAE SEROTYPES DISTRIBUTION AMONG ADULTS HOSPITALIZED WITH PNEUMONIA AND INVASIVE PNEUMOCOCCAL DISEASE IN MONTEVIDEO URUGUAY. (E-Poster Gallery) - Jun 7, 2022 - Abstract #ISPPD2022ISPPD_606;
In 2010 PCV13v replaced PCV7...Additional serotypes to be included will add better coverage. These findings support the administration of PCV in adult population.
- PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
INFANT PNEUMOCOCCAL CONJUGATE VACCINE PROGRAMS RESULT IN SUBSTANTIAL COST-SAVINGS AND CASES AVERTED IN THE UNITED KINGDOM ([VIRTUAL]) - May 19, 2022 - Abstract #ESPID2022ESPID_1379;
This reduction in disease cases produced total cost savings of £681,763,795 and 79,027 QALYs gained over the period. Vaccination costs were more than offset by the direct medical cost savings from fewer cases of IPD, inpatient pneumonia, and OM.
- || PCV7 / Pfizer, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Retrospective data, Review, Journal: Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis. (Pubmed Central) - Oct 27, 2021
Data from Portugal, Greece and, to a lesser extent, Italy were sparse, thus improved surveillance is needed. Pneumococcal vaccination uptake, particularly among the elderly and adults with chronic and immunosuppressing conditions, should be improved, including shift to a higher-valency pneumococcal conjugate vaccine when available.
- Synflorix (10-valent pneumococcal conjugate vaccine) / GSK
[VIRTUAL] Serotype Distribution by Age of Remaining Invasive Pneumococcal Disease After Long-Term PCV10/13 Use: The PSERENADE Project () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2039;
ST distribution of remaining IPD differed between PCV10 and PCV13 sites and between age groups. Higher-valency PCVs under evaluation target over half of remaining IPD cases, but some prevalent STs are not included in known investigational products.
- || PCV7 / Pfizer, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Clinical, Journal: Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance. (Pubmed Central) - Sep 19, 2021
Routine introduction of PCV13 substantially reduced the incidence of childhood IPD and pneumonia in rural Gambia, including elimination of vaccine-type IPD in infants. Other low-income countries can expect substantial impact from the introduction of PCV13 using a schedule of three primary doses.
- || PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Clinical, Journal: Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use. (Pubmed Central) - Aug 20, 2021
P=N/A
Other low-income countries can expect substantial impact from the introduction of PCV13 using a schedule of three primary doses. IPD incidence decreased further in every age group after PCV13 introduction, suggesting both direct vaccination effects in the infant population and indirect effects in adults.
- | PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Journal, HEOR: Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea. (Pubmed Central) - Jun 24, 2021
IPD incidence decreased further in every age group after PCV13 introduction, suggesting both direct vaccination effects in the infant population and indirect effects in adults. A NIP using PCV13 was estimated to have a more substantial public health impact and be cost-saving compared to a program with PCV10 due to broader serotype coverage.
- | PCV7 / Pfizer, PF-06482077 / Pfizer, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Journal: Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines. (Pubmed Central) - May 28, 2021
Substantial residual PCV13-serotype IPD proportions observed among all ages imply limits to indirect protection afforded by the pediatric PCV13 program at the current uptake level and suggest the adult PPSV23 program alone is insufficient. Higher-valent PCVs have the potential to address a substantial proportion of remaining IPD cases among all age groups.
- | PCV7 / Pfizer, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Journal: Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: A modelling analysis. (Pubmed Central) - Apr 28, 2021
A higher valent PCV13 replaced PCV7 in late 2009...PCV13 vaccination was estimated to have prevented 175.2 million cases of all pneumococcal diseases and 624,904 deaths globally between 2010 and 2019. These results demonstrate the substantial public health impact of PCV13 and highlight the importance of increasing the global reach of PCV programs.
- PCV7 / Pfizer
[VIRTUAL] PNEUMOCOCCAL NASOPHARYNGEAL CARRIAGE OF FULLY VACCINATED 6-12 MONTH OLD CHILDREN IN ENGLAND, PRIOR TO A REDUCTION IN INFANT PCV13 DOSES IN THE UK IMMUNISATION SCHEDULE. (Hall 05) - Apr 7, 2021 - Abstract #ESPID2021ESPID_265;
P=N/A
Following a two-dose priming schedule there is a low prevalence of vaccine serotype carriage. These data provide an important baseline for comparison with carriage and seroprevalence data after a single priming dose.
- || PCV7 / Pfizer, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Clinical, Journal: Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study. (Pubmed Central) - Jan 15, 2021
However, a rebound in cases among children and adults since 2015, driven by several emerging non-PCV13 serotypes, jeopardises the long-term PCV benefits. These findings, if confirmed in the coming years, should be considered in the development of next-generation PCVs and might guide policy makers in the selection of future pneumococcal vaccines.
- | PCV7 / Pfizer, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Observational data, Retrospective data, Journal: Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study. (Pubmed Central) - Jan 15, 2021
During the PCV10 period, dominant serotype 19A clones differed from those detected during previous vaccine periods. Whether changes in epidemiology resulted from the vaccine switch or also from natural evolution remains to be further elucidated.
- PCV7 / Pfizer, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
[VIRTUAL] Twenty-year impact of Pneumococcal Conjugate Vaccines (PCV) on the burden of invasive pneumococcal disease in US children less than 5 years of age () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_2181;
Background: Clinical trials of PCV7 demonstrate significant reductions in vaccine-type (VT) invasive pneumococcal disease (IPD), clinically diagnosed pneumonia in children less than 5 years of age and VT acute otitis media in children < 2 years of age... The substantial public health impact of PCVs over the last two decades, as measured in cases and deaths averted in children less than 5 years, re-enforces the important role vaccines play in reducing the burden of serious disease in children.
- PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
[VIRTUAL] Impact of 7-Valent and 13-Valent Pneumococcal Conjugate Vaccines in the United States: A Systematic Literature Review () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_1487;
PCVs have greatly decreased multiple manifestations of pneumococcal disease in the US. However, granular data on the frequency and morbidity associated with specific pneumococcal diseases and on associated HCRU are needed to quantify the public-health impact of these vaccines.
- || PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Clinical, Journal: A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands. (Pubmed Central) - Jul 25, 2020
A public health analysis of pneumonia and IPD outcomes in a randomized controlled trial found substantial burden reduction following adult PCV13 immunization implemented in a setting with an ongoing infant PCV7-PCV10 program. VPDIs were higher among at-risk adults.
- ceftriaxone / Generic mfg., amoxicillin / Generic mfg.
[VIRTUAL] CHANGES IN ANTIMICROBIAL SUSCEPTIBILITY OF STREPTOCOCCUS PNEUMONIAE 1999-2019 AT A NORTHEAST OHIO ACADEMIC MEDICAL CENTER FOLLOWING INTRODUCTION OF 7- AND 13-VALENT CONJUGATE PNEUMOCOCCAL VACCINES () - Jun 22, 2020 - Abstract #ISPPD2020ISPPD_129;
Background: Antimicrobial resistance has presented a major clinical challenge, with many resistant serotypes included in 7- and 13-valent conjugated vaccines (PCV7, PCV13, Prevnar, Pfizer) introduced in 200 and 2010, respectively... Antimicrobial susceptibility of pneumococci to penicillin, amoxicillin, ceftriaxone and trimethoprim-sulfamethoxazole improved after introduction of conjugate vaccines, while susceptibility to azithromycin and clindamycin did not, with almost 40% of isolates resistant to azithromycin in 2017-2019.
- [VIRTUAL] CHANGES IN STREPTOCOCCUS PNEUMONIAE SEROTYPE DISTRIBUTIONS 1999-2019 AT A NORTHEAST OHIO ACADEMIC MEDICAL CENTER FOLLOWING INTRODUCTION OF 7- AND 13-VALENT CONJUGATE PNEUMOCOCCAL VACCINES () - Jun 22, 2020 - Abstract #ISPPD2020ISPPD_83;
The proportion of PCV7 and PCV13 serotypes decreased considerably after their introduction. P23 and the two conjugated vaccines in development increase coverage of serotypes not in PCV13.
- PCV7 / Pfizer, Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Pneumococcal vaccine serotypes causing community-acquired pneumonia in adults with and without comorbidities in Spain using the urinary antigen detection test (the CAPA study) (Arena 1) - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_4157;
In Spain PCV7/PCV13 were available for children from 2000 and 2010 respectively and afforded by parents (estimated uptake 61%) until 2015-2016, when PCV13 was introduced in the immunization program (IP)... In Spain PCV13 serotypes remain a significant cause of CAP in adults with and without underlying conditions 6 years after PCV13 introduction for infants and after >14 years of PPV23 recommended for adults at risk or by age.